跳至主要内容
临床试验/CTRI/2021/07/034559
CTRI/2021/07/034559进行中(未招募)未知

A prospective, observational, real world evidence study to assess effectiveness & safety of HAPID�® (Un-denatured Type II Collagen 40 mg and Aflapin 100 mg) of Wockhardt Limited in the management of patients with Knee Osteoarthritis - HAPID PMS

Wockhardt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Ambulatory adult patient, clinically or radiologically confirmed diagnosis of Knee Osteoarthritis newly prescribed with HAPIDÃ?® (Un-denatured Type II Collagen and Aflapin), willing to provide written informed consent and comply to the study as per protocol

排除标准

  • 1.History or evidence of hypersensitivity to any component of study medication
  • 2.History of viscosupplementation within 9 months prior to date of screening
  • 3.History of allergy to eggs or chicken
  • 4.Pregnant or lactating women
  • 5.Any other reason which in opinion of investigator preludes participation in study

研究者

发起方
Wockhardt Ltd

相似试验